Europe Sarcopenia Treatment Market – Industry Trends and Forecast to 2030

Pharmaceutical
Published Report
Nov 2023
Europe
350 Pages
No of Tables: 291
No of Figures: 43

Europe Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.

Europe Sarcopenia Treatment Market Analysis and Size

The primary factors driving the growth of the Europe sarcopenia treatment market is the rising prevalence of sarcopenia. In addition, growing awareness of sarcopenia and its detrimental effect on health is another key driver for market growth. Lifestyle factors such as poor nutrition and sedentary behavior also influence the market. However, the lack of standardized diagnosis and the high cost of treatment and intervention are expected to restrain market growth.

Data Bridge Market Research analyzes that the Europe sarcopenia treatment market is expected to reach the value of USD 1,033,968.39 thousand by 2030, at a CAGR of 4.6% during the forecast period.

This market report also covers pricing analysis and technological advancements in depth.

Report Metric	Details
Forecast Period	2023 to 2030
Base Year	2022
Historic Years	2021 (Customizable to 2015 - 2020)
Quantitative Units	Revenue in USD Thousand, Volumes in Units, Pricing in USD
Segments Covered	Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
Countries Covered	Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe
Market Players Covered	Abbott., Nestlé Health Science (A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies, BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Healing Pharma India Pvt. Ltd., OPKO Health, Inc., NMD PHARMA A/S, Regeneron Pharmaceuticals Inc., Biophytis, ARMGO Pharma, Inc. Rejuvenate Biomed NV. And among others

Market Definition

Sarcopenia treatment refers to the commercial landscape related to products and services aimed at preventing, managing, or addressing sarcopenia—a progressive age-related condition characterized by the loss of skeletal muscle mass, strength, and function, typically beginning around the age of 30 and accelerating after the age of 60.

Sarcopenia has significant consequences on an individual's overall health and quality of life. There is a corresponding decline in muscle strength and endurance, making everyday tasks more challenging and increasing the risk of falls and fractures as muscle mass decreases. In addition, sarcopenia can lead to metabolic changes, insulin resistance, and an increased likelihood of obesity.

Europe Sarcopenia Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

Rising Prevalence of Sarcopenia

Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function, particularly in older adults. They naturally experience a gradual loss of muscle mass and function, which predisposes them to sarcopenia as people age. The number of individuals at risk of developing sarcopenia is increasing steadily with the world's population aging. This demographic shift directly drives the demand for sarcopenia treatment options. The increasing prevalence of the condition means that more individuals require diagnosis and treatment, creating a larger patient pool for the sarcopenia treatment market.

People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses such as diabetes, cardiovascular disease, and cancer can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.

The demand for effective interventions to prevent or manage sarcopenia is expected to increase, fostering research, development, and innovation in the field of sarcopenia treatment as the world's population continues to age, which is expected to drive market growth.

Growing Awareness of Sarcopenia and its Detrimental Effects on Health

The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.

Opportunity

Strategic Initiatives by the Key Market Players

The sarcopenia treatment market is witnessing substantial growth as it is a progressive age-related condition characterized by the loss of muscle mass, strength, and function. It is a significant health concern, particularly among the elderly population, as it can lead to decreased mobility, increased risk of falls and fractures, and a decline in overall quality of life due to which key market players are proactively taking strategic initiatives for product development. Thus, opening up opportunities for market expansion and advancement.

Strategic initiative includes collaborations and partnerships with research institutions, healthcare organizations, and academic centers. Market players can leverage their knowledge and resources to accelerate the development and commercialization of sarcopenia treatments by collaborating with experts in the field. Such collaborations facilitate knowledge exchange, access to patient populations for clinical trials, and the pooling of expertise to drive innovation in the market.

Restraint / Challenge

Lack of Standardized Diagnostics

The absence of standardized diagnostic criteria may result in delayed diagnosis or missed cases of sarcopenia. Healthcare professionals may not routinely screen for the condition, especially in adults, which can hinder early intervention and treatment initiation. Without a standardized diagnosis, healthcare providers may use different criteria and methods to identify sarcopenia. This inconsistency can lead to variations in the reported prevalence of sarcopenia and the number of diagnosed cases, making it challenging to assess the true market size and demand for treatments.

Sarcopenia is a multifaceted condition that can affect individuals differently based on factors such as age, gender, and comorbidities. Patient groups may be heterogeneous, making it challenging to conduct clinical trials and research to evaluate treatment efficacy accurately without standardized diagnostic criteria. Clinical trials for sarcopenia treatments may use different diagnostic criteria, making it challenging to compare the results of various studies. This lack of standardization can hinder the development and approval of new treatments by regulatory agencies.

Recent Developments

In February 2023, Nestlé Health Science announced that they entered into a research collaboration with EraCal Therapeutics, to identify novel nutraceuticals relevant to controlling food intake. This will increase the company's product portfolio and overall revenue.
In November 2022, Abbott announced that it has been awarded by the Consumer Technology Association (CTA) with three CES 2023 innovation awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.

Europe Sarcopenia Treatment Market Scope

The Europe sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

Vitamin/Dietary Supplements
Medications
Others

On the basis of treatment type, the market is segmented into medications, vitamin/dietary supplements, and others.

Type

Primary Sarcopenia
Secondary Sarcopenia

On the basis of type the market is segmented into primary sarcopenia and secondary sarcopenia.

Stages

Pre-Sarcopenia
Sarcopenia
Severe Sarcopenia

On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.

Route of Administration

Oral
Injectable
Others

On the basis of route of administration the market is segmented into oral, injectable, and others.

Gender

Male
Female

On the basis of gender the market is segmented into male and female.

End User

Hospitals
Speciality Clinics
Home Healthcare
Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

Direct Tender
Retail Sales
Others

On the basis of distribution channel the market is segmented into direct tender, retail sales, and others.

Europe Sarcopenia Treatment Market Regional Analysis/Insights

The Europe sarcopenia treatment market is analyzed and market size insights and trends are provided by country, treatment type, type, stages, route of administration, gender, end user, and distribution channel.

The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe.

Germany is expected to dominate the Europe sarcopenia treatment market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the region.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Sarcopenia Treatment Market Share Analysis

The Europe sarcopenia treatment market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major market players operating in the Europe sarcopenia treatment market are Abbott., Nestlé Health Science (A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Healing Pharma India Pvt. Ltd. and among others.

SKU-70293

TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT

TABLE 2 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 EUROPE MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 EUROPE OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 8 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 13 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 15 EUROPE PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 EUROPE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 EUROPE SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 19 EUROPE ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 EUROPE INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 23 EUROPE MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 EUROPE FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 26 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 28 EUROPE SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 EUROPE HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 32 EUROPE DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 34 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 35 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 37 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 38 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 40 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 41 EUROPE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 42 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 46 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 47 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 48 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 49 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 51 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 52 GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 GERMANY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 55 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 56 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 57 GERMANY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 GERMANY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 GERMANY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 GERMANY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 GERMANY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 62 GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 63 GERMANY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 64 GERMANY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 65 GERMANY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 66 GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 67 GERMANY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 68 FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 FRANCE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 70 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 72 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 73 FRANCE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 74 FRANCE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 75 FRANCE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 76 FRANCE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 FRANCE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 78 FRANCE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 79 FRANCE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 80 FRANCE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 81 FRANCE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 83 FRANCE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 84 U.K. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 U.K. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 88 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 89 U.K. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 U.K. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 U.K. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 U.K. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 U.K. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 94 U.K. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 95 U.K. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 96 U.K. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 97 U.K. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 U.K. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 99 U.K. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 100 ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 ITALY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 104 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 105 ITALY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 106 ITALY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 ITALY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 108 ITALY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 ITALY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 110 ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 111 ITALY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 112 ITALY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 113 ITALY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 ITALY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 115 ITALY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 116 SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 SPAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 120 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 121 SPAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 SPAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 SPAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 SPAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 SPAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 126 SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 127 SPAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 128 SPAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 129 SPAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 131 SPAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 132 RUSSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 RUSSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 134 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 136 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 137 RUSSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 RUSSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 RUSSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 140 RUSSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 RUSSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 142 RUSSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 143 RUSSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 144 RUSSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 145 RUSSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 RUSSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 147 RUSSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 148 TURKEY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 TURKEY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 152 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 153 TURKEY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 TURKEY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 TURKEY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 TURKEY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 TURKEY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 158 TURKEY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 159 TURKEY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 160 TURKEY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 161 TURKEY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 TURKEY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 163 TURKEY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 164 BELGIUM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 165 BELGIUM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 168 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 169 BELGIUM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 170 BELGIUM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 171 BELGIUM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 BELGIUM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 BELGIUM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 174 BELGIUM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 175 BELGIUM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 176 BELGIUM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 177 BELGIUM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 BELGIUM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 179 BELGIUM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 180 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 NETHERLANDS MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 184 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 185 NETHERLANDS VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 186 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 NETHERLANDS PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 188 NETHERLANDS SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 189 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 190 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 191 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 192 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 193 NETHERLANDS HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 195 NETHERLANDS RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 196 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 SWIZTERLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 200 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 201 SWIZTERLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 202 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 203 SWIZTERLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 204 SWIZTERLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 206 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 207 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 208 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 209 SWIZTERLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 211 SWIZTERLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 212 DENMARK SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 DENMARK MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 216 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 217 DENMARK VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 DENMARK SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 219 DENMARK PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 DENMARK SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 DENMARK SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 222 DENMARK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 223 DENMARK SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 224 DENMARK SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 225 DENMARK HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 DENMARK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 227 DENMARK RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 228 NORWAY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 229 NORWAY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 230 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 232 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 233 NORWAY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 234 NORWAY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 NORWAY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 236 NORWAY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 237 NORWAY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 238 NORWAY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 239 NORWAY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 240 NORWAY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 241 NORWAY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 242 NORWAY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 243 NORWAY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 244 SWEDEN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 SWEDEN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 248 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 249 SWEDEN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 SWEDEN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 251 SWEDEN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 252 SWEDEN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 253 SWEDEN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 254 SWEDEN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 255 SWEDEN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 256 SWEDEN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 257 SWEDEN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 258 SWEDEN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 259 POLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 POLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 263 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 264 POLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 265 POLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 266 POLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 267 POLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 268 POLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 269 POLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 270 POLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 271 POLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 272 POLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 273 POLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 POLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 275 FINLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 FINLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 279 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 280 FINLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 FINLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 282 FINLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 FINLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 284 FINLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 285 FINLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 286 FINLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 287 FINLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 288 FINLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 289 FINLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 290 FINLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 291 REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

How big is the Europe sarcopenia treatment market?

The Europe sarcopenia treatment market size will be worth USD 1,033,968.39 thousand by 2030.

What is the growth rate of the Europe sarcopenia treatment market?

The growth rate of the Europe sarcopenia treatment market is 4.6% by the forecasted time period.

What are the growth drivers of the Europe sarcopenia treatment market?

The rising prevalence of sarcopenia & growing awareness of sarcopenia and its detrimental effects on health are the growth drivers of the Europe sarcopenia treatment market.

What are the factors on which the Europe sarcopenia treatment market research is based on?

Treatment type, type, stages, route of administration, gender, end user, and distribution channel are the factors on which the Europe sarcopenia treatment market research is based.

Which are the major companies in the Europe sarcopenia treatment market?

Major companies in the Europe sarcopenia treatment market are Abbott., Nestlé Health Science (A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India & Healing Pharma India Pvt. Ltd.

BROWSE RELATED Press Release

Rising Prevalence of Sarcopenia is Expected to Driver Growth of Global Sarcopenia Treatment Market

Rising Prevalence of Sarcopenia is Expected to Drive the Growth of North America Sarcopenia Treatment Market

Rising Prevalence of Sarcopenia is Expected to Drives the Growth of Asia-Pacific Sarcopenia Treatment Market

Rising Prevalence of Sarcopenia is Expected to Drive the Growth of Europe Sarcopenia Treatment Market

Free Sample Report

CHOOSE LICENCE TYPE

Enterprise User 4200.00
Single User 3500.00
DBMR Factbook 2000.00
DBMR Prime 5500.00
DBMR Supreme 7500.00

Buy Now

Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report

Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.